Sarepta Therapeutics Inc (SRPT)
104.54
-4.57
(-4.19%)
USD |
NASDAQ |
Nov 15, 16:00
106.88
+2.34
(+2.24%)
Pre-Market: 20:00
Sarepta Therapeutics Research and Development Expense (TTM): 800.09M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 800.09M |
| June 30, 2024 | 769.90M |
| March 31, 2024 | 832.10M |
| December 31, 2023 | 877.39M |
| September 30, 2023 | 895.67M |
| June 30, 2023 | 918.08M |
| March 31, 2023 | 928.52M |
| December 31, 2022 | 877.09M |
| September 30, 2022 | 860.58M |
| June 30, 2022 | 782.99M |
| March 31, 2022 | 770.28M |
| December 31, 2021 | 771.18M |
| September 30, 2021 | 781.12M |
| June 30, 2021 | 832.45M |
| March 31, 2021 | 781.35M |
| December 31, 2020 | 722.34M |
| September 30, 2020 | 738.24M |
| June 30, 2020 | 681.76M |
| March 31, 2020 | 606.50M |
| December 31, 2019 | 560.91M |
| September 30, 2019 | 483.98M |
| June 30, 2019 | 436.61M |
| March 31, 2019 | 446.19M |
| December 31, 2018 | 401.84M |
| September 30, 2018 | 300.08M |
| Date | Value |
|---|---|
| June 30, 2018 | 247.73M |
| March 31, 2018 | 183.79M |
| December 31, 2017 | 166.71M |
| September 30, 2017 | 193.02M |
| June 30, 2017 | 193.12M |
| March 31, 2017 | 178.56M |
| December 31, 2016 | 188.27M |
| September 30, 2016 | 158.90M |
| June 30, 2016 | 161.22M |
| March 31, 2016 | 146.06M |
| December 31, 2015 | 146.39M |
| September 30, 2015 | 135.85M |
| June 30, 2015 | 121.03M |
| March 31, 2015 | 112.49M |
| December 31, 2014 | 94.23M |
| September 30, 2014 | 88.48M |
| June 30, 2014 | 87.71M |
| March 31, 2014 | 80.05M |
| December 31, 2013 | 72.91M |
| September 30, 2013 | 60.67M |
| June 30, 2013 | 50.49M |
| March 31, 2013 | 51.36M |
| December 31, 2012 | 52.40M |
| September 30, 2012 | 58.27M |
| June 30, 2012 | 62.96M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
560.91M
Minimum
Dec 2019
928.52M
Maximum
Mar 2023
789.43M
Average
782.17M
Median
Research and Development Expense (TTM) Benchmarks
| Catalyst Pharmaceuticals Inc | 10.82M |
| Madrigal Pharmaceuticals Inc | 281.71M |
| Vertex Pharmaceuticals Inc | 3.456B |
| Viking Therapeutics Inc | 91.16M |
| Regenxbio Inc | 213.82M |